13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001595855
Total reported value
$1.1B
$1.1B
39 檔
28.9%
According to the latest 13F quarterly dataset, Opaleye Management Inc. managed an equity portfolio of $1.1B at the end of Q4 2024, spanning 39 distinct U.S. exchange-listed positions.
Opaleye Management Inc. executed strategic sector rebalancing during Q4 2024, establishing 6 new positions while fully exiting 11 holdings and trimming 12 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | HROW | Harrow Inc | Stock-Other | 23.43% | -3.92% | — | |
| 2 | TGTX | Tg Therapeutics Inc | Stock-Healthcare | 11.90% | +0.32% | -0.88% | |
| 3 | CDXS | Codexis Inc | Stock-Other | 7.38% | -0.07% | +0.80% | |
| 4 | ETON | Eton Pharmaceuticals Inc | Stock-Other | 6.65% | +0.08% | +2.59% | |
| 5 | OCUL | Ocular Therapeutix Inc | Stock-Other | 6.49% | -0.14% | -13.58% | |
| 6 | ARVN | Arvinas Inc | Stock-Other | 5.89% | — | +29.48% | |
| 7 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 4.90% | -3.42% | — | |
| 8 | IMNM | Immunome Inc | Stock-Other | 3.79% | — | +64.85% | |
| 9 | LQDA | Liquidia CORP | Stock-Other | 3.49% | +5.97% | — | |
| 10 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 2.24% | -0.23% | -8.13% | |
| 11 | DNA | Ginkgo Bioworks Holdings Inc | Stock-Other | 2.06% | — | +46.31% | |
| 12 | CRGX | Cargo Therapeutics Inc | Stock-Other | 1.89% | — | +38.52% | |
| 13 | TARA | Protara Therapeutic Inc | Stock-Other | 1.69% | — | +8.56% | |
| 14 | TRVI | Trevi Therapeutics Inc | Stock-Other | 1.67% | -0.02% | -9.75% | |
| 15 | JSPR | Jasper Therapeutics Inc | Stock-Other | 1.50% | — | +13.15% | |
| 16 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 1.46% | — | -2.99% | |
| 17 | ✓ | Acelyrin Inc | Stock-Other | 1.26% | — | +18.03% | |
| 18 | NRIX | Nurix Therapeutics Inc | Stock-Other | 1.25% | — | -9.88% | |
| 19 | XOMA | Xoma Royalty Corporation | Stock-Other | 1.15% | +0.06% | — | |
| 20 | PCVX | Vaxcyte Inc | Stock-Other | 1.07% | — | -11.76% | |
| 21 | GOSS 5 06-01-27Bond | Gossamer Bio Inc | Bond | 1.07% | — | +43.75% | |
| 22 | ZNTL | Zentalis Pharmaceuticals Inc | Stock-Other | 0.94% | +0.18% | +82.78% | |
| 23 | ✓ | Biodesix Inc | Stock-Other | 0.93% | — | -9.17% | |
| 24 | KPTI 3 10-15-25Bond | Karyopharm Therapeutics | Bond | 0.82% | — | — | |
| 25 | NUVL | Nuvalent Inc-a | Stock-Other | 0.80% | — | -8.59% | |
| 26 | GOSS | Gossamer Bio Inc | Stock-Other | 0.71% | — | +22.51% | |
| 27 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 0.71% | -0.28% | — | |
| 28 | EPIEUR | Essa Pharma Inc | Stock-Other | 0.69% | — | — | |
| 29 | ABCL | Abcellera Biologics Inc | Stock-Other | 0.49% | — | +20.63% | |
| 30 | URGN | UroGen Pharma Ltd. | Stock-Other | 0.41% | +1.41% | -45.56% | |
| 31 | RZLT | Rezolute Inc | Stock-Other | 0.40% | +0.44% | -0.34% | |
| 32 | ✓ | Immatics NV | Stock-Other | 0.21% | — | — | |
| 33 | IBIO | Ibio Inc | Stock-Other | 0.16% | — | — | |
| 34 | LXEO | Lexeo Therapeutics Inc | Stock-Other | 0.15% | — | — | |
| 35 | RGNX | Regenxbio Inc | Stock-Other | 0.11% | — | — | |
| 36 | VTYXUSD | Ventyx Biosciences Inc | Stock-Other | 0.11% | — | — | |
| 37 | PEPG | Pepgen Inc | Stock-Other | 0.07% | — | -38.62% | |
| 38 | STOK | Stoke Therapeutics Inc | Stock-Other | 0.05% | -0.93% | — | |
| 39 | ADGM | Adagio Medical Holdings Inc | Stock-Other | 0.02% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ETON | Eton Pharmaceuticals Inc | +3.9% | +2.59% | Add |
| 2 | TGTX | Tg Therapeutics Inc | +3% | -0.88% | Trim |
| 3 | CDXS | Codexis Inc | +2.9% | +0.80% | Add |
| 4 | TARA | Protara Therapeutic Inc | +1.2% | +8.56% | Add |
| 5 | DNA | Ginkgo Bioworks Holdings Inc | +1% | +46.31% | Add |
| 6 | IMNM | Immunome Inc | +0.8% | +64.85% | Add |
| 7 | ARVN | Arvinas Inc | +0.7% | +29.48% | Add |
| 8 | EPIEUR | Essa Pharma Inc | +0.7% | NEW | New buy |
| 9 | LQDA | Liquidia CORP | +0.7% | — | Unchanged |
| 10 | NAMS | NewAmsterdam Pharma Company N.V. | +0.5% | -2.99% | Trim |
| 11 | RYTM | Rhythm Pharmaceuticals Inc | +0.5% | — | Unchanged |
| 12 | JSPR | Jasper Therapeutics Inc | +0.4% | +13.15% | Add |
| 13 | GOSS 5 06-01-27Bond | Gossamer Bio Inc | +0.4% | +43.75% | Add |
| 14 | ZNTL | Zentalis Pharmaceuticals Inc | +0.4% | +82.78% | Add |
| 15 | TRVI | Trevi Therapeutics Inc | +0.2% | -9.75% | Trim |
| 16 | ✓ | Immatics NV | +0.2% | NEW | New buy |
| 17 | KPTI 3 10-15-25Bond | Karyopharm Therapeutics | +0.2% | — | Unchanged |
| 18 | LXEO | Lexeo Therapeutics Inc | +0.2% | NEW | New buy |
| 19 | ABCL | Abcellera Biologics Inc | +0.1% | +20.63% | Add |
| 20 | RGNX | Regenxbio Inc | +0.1% | NEW | New buy |
| 21 | VTYXUSD | Ventyx Biosciences Inc | +0.1% | NEW | New buy |
| 22 | GOSS | Gossamer Bio Inc | +0.1% | +22.51% | Add |
| 23 | STOK | Stoke Therapeutics Inc | +0.1% | NEW | New buy |
| 24 | XOMA | Xoma Royalty Corporation | +0.1% | — | Unchanged |
| 25 | IBIO | Ibio Inc | 0% | — | Unchanged |
| 26 | RZLT | Rezolute Inc | 0% | -0.34% | Trim |
| 27 | ADGM | Adagio Medical Holdings Inc | 0% | — | Unchanged |
| 28 | CRGX | Cargo Therapeutics Inc | -0.1% | +38.52% | Add |
| 29 | PTGX | Protagonist Therapeutics Inc | -0.1% | — | Unchanged |
| 30 | EWTX | Edgewise Therapeutics Inc | -0.1% | -8.13% | Trim |
| 31 | RGLS | Regulus Therapeutics Inc | -0.1% | EXIT | Sold out |
| 32 | ✓ | -0.2% | EXIT | Sold out | |
| 33 | PEPG | Pepgen Inc | -0.2% | -38.62% | Trim |
| 34 | ✓ | Biodesix Inc | -0.2% | -9.17% | Trim |
| 35 | SYRS | Syros Pharmaceuticals Inc | -0.2% | EXIT | Sold out |
| 36 | RVNCEUR | Revance Therapeutics Inc | -0.2% | EXIT | Sold out |
| 37 | ALLKGUSD | Allakos Inc | -0.3% | EXIT | Sold out |
| 38 | RLMD | Relmada Therapeutics Inc | -0.3% | EXIT | Sold out |
| 39 | NUVL | Nuvalent Inc-a | -0.3% | -8.59% | Trim |
| 40 | ✓ | Acelyrin Inc | -0.3% | +18.03% | Add |
| 41 | NRIX | Nurix Therapeutics Inc | -0.3% | -9.88% | Trim |
| 42 | LYEL | Lyell Immunopharma, Inc. | -0.3% | EXIT | Sold out |
| 43 | CPRX | Catalyst Pharmaceuticals Inc | -0.4% | EXIT | Sold out |
| 44 | URGN | UroGen Pharma Ltd. | -0.5% | -45.56% | Trim |
| 45 | PCVX | Vaxcyte Inc | -0.6% | -11.76% | Trim |
| 46 | CYTK | Cytokinetics Inc | -0.7% | EXIT | Sold out |
| 47 | OCUL | Ocular Therapeutix Inc | -0.8% | -13.58% | Trim |
| 48 | APLT | Applied Therapeutics Inc | -1.9% | EXIT | Sold out |
| 49 | KROS | Keros Therapeutics Inc | -3.8% | EXIT | Sold out |
| 50 | HROW | Harrow Inc | -6.5% | — | Unchanged |
According to official SEC Form 13F filings, Opaleye Management Inc. reported a total U.S. public equity portfolio value of $1.1B across 39 disclosed positions in Q4 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including HROW, TGTX, CDXS) accounted for 28.9% of total reported equity market value during Q4 2024.
Top New Position Initiated
EPIEUR
市值: $4.0M
Top Position Liquidated / Trimmed
KROS
前期市值: $23.0M
During Q4 2024, Opaleye Management Inc.'s top holdings by market value included HROW (23.4%)、TGTX (11.9%)、CDXS (7.4%). The largest single position, HROW, represented 23.4% of total portfolio value.
In Q4 2024, Opaleye Management Inc. made 42 total portfolio adjustments, initiating 6 new buys, adding to 13 positions, trimming 12 holdings, and fully liquidating 11 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.